Cannabinoid products from hemp; sale regulated by Revenue Department, licensure required; tax imposed
SB255 would create a new regulatory framework for “novel cannabinoid products” made from hemp, including products containing CBD, THCa, delta-8 THC, HHC, and other THC compounds. Beginning in 2026, businesses that want to sell these products would need a retailer license from the Department of Revenue, with annual renewal, possible background checks, zoning and business-license compliance, and separate licensing for each location. The bill also bars businesses that already hold an alcohol retail license from obtaining a cannabinoid retailer license, and it requires licensed retailers to devote at least 80 percent of merchandise and sales on the premises to novel cannabinoid products.
The bill would also require the Department of Agriculture and Industries to establish testing and labeling standards before any product can be sold. Each product would have to be tested by an independent third-party lab for potency, purity, and safety, and labels would need to disclose total cannabinoid content per serving and include health-risk information. Retailers would have to submit testing results and labels for approval and keep approval certifications on site. The Department of Revenue could suspend or revoke licenses and impose penalties for false applications, disqualifying criminal convictions, sales of unapproved products, or other rule violations.
SB255 would impose a 6 percent tax on sales of novel cannabinoid products and direct the Department of Revenue to collect and remit the tax quarterly. All license fees, civil penalties, and tax proceeds would go into a new Novel Cannabinoid Safety Fund, which would be used to administer and enforce the act and to protect public health and safety from unregulated cannabinoid products. The bill also authorizes civil penalties of up to $10,000 for selling these products without a license and requires annual reporting to the Legislature on licenses issued, revenues collected, fund use, and any recommended follow-up legislation.
The overall sentiment reflected in the bill text is cautious and regulatory rather than prohibitive: the findings emphasize public health concerns, mislabeled products, and sales in convenience stores and alcohol-serving establishments, while also describing the measure as a way to create a sustainable revenue stream. No committee transcript or vote record is provided, so there is no direct evidence of debate or bipartisan support/opposition in the available materials. The bill’s status as indefinitely postponed suggests it did not advance, but the record here does not show the specific reasons.
The main point of contention apparent from the bill itself is the scope of regulation and the restriction on businesses that sell alcohol, which would exclude many existing retailers from participating in the market. Another likely issue is the combination of licensing, testing, labeling, and tax requirements, which would impose new compliance costs on hemp-product sellers and could significantly reshape the retail market for hemp-derived intoxicating products in Alabama.
SB255 would amend Alabama law by creating a new state licensing, testing, labeling, enforcement, and taxation regime for hemp-derived cannabinoid products classified as novel cannabinoid products. It would shift oversight primarily to the Department of Revenue, with the Department of Agriculture and Industries responsible for product testing and label approval, and would establish the Novel Cannabinoid Safety Fund to receive fees, penalties, and tax revenue. The bill would directly affect hemp retailers, convenience stores, smoke shops, and any business selling intoxicating hemp-derived products, while excluding alcohol retailers from licensure.
The bill is framed in a generally supportive, public-safety-oriented way, with sponsors presenting it as a response to rapid growth in hemp-derived intoxicating products and concerns about unregulated sales, mislabeling, and youth access. The text suggests an intent to regulate rather than ban the products, while also generating state revenue. Because no committee discussion or votes are included, the available record does not show specific support or opposition from legislators or stakeholders, though the bill’s indefinite postponement indicates it did not ultimately move forward.
The most notable likely points of contention are the prohibition on licensure for businesses that sell alcoholic beverages, the requirement that licensed premises be overwhelmingly devoted to cannabinoid products, and the new compliance burden created by mandatory third-party testing, labeling approval, and a 6 percent tax. Retailers and alcohol-serving businesses would likely view these provisions as restrictive and costly, while supporters would likely argue they are necessary to protect consumers from unsafe or mislabeled hemp-derived THC products. The bill also raises broader policy tension over whether hemp-derived intoxicants should be treated more like consumer goods or like controlled substances requiring tight state oversight.